Adam Marler, MD
Cardiovascular Disease · Thomasville, GANPI 1962667931
Payments from drug & device makers
Across 255 payments — averaging $60.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- Medtronic$2K
- Novartis$487
- E.r. Squibb & Sons, L.L.C.$396
- Pfizer$364
- Amgen$306
- plus $1K from 19 others
What the payments were for
- Consulting fees$5,07033%
- Speaking & faculty fees$4003%
- Travel & lodging$3,61723%
- Food & beverage$6,38741%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 62 | $10,554 |
| Medtronic(2 entities) | 22 | $1,948 |
| Novartis | 25 | $487 |
| E.r. Squibb & Sons, L.L.C. | 27 | $396 |
| Pfizer | 26 | $364 |
| Amgen | 13 | $306 |
| Merck | 13 | $228 |
| Boehringer Ingelheim | 11 | $220 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $176 |
| Abiomed | 1 | $120 |
| AstraZeneca | 7 | $111 |
| Shockwave Medical, Inc | 3 | $74 |
| Cvrx, Inc. | 2 | $66 |
| Novo Nordisk | 4 | $65 |
| Arbor Pharmaceuticals, Inc. | 4 | $64 |
| Johnson & Johnson | 5 | $62 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Bayer | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Braemar Manufacturing, LLC | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$5,592
- AVEIR$2,644
- Allure CRT Pacemaker$261
- Unify Assura CRT Defibrillator$155
- Micra$136
- Quadra Assura CRT Defibrillator$136
- JOT DX$133
- Reveal LINQ$125
- Confirm Rx$123
- CARDIOMEMS$120
- Impella$120
- Repatha$116
How this compares
$15,481 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 612 | $498,455 |
| EntrestoSacubitril/Valsartan | 498 | $399,220 |
| VyndamaxTafamidis | 17 | $364,132 |
| FarxigaDapagliflozin Propanediol | 326 | $242,139 |
| JardianceEmpagliflozin | 125 | $107,858 |
| XareltoRivaroxaban | 105 | $90,445 |
| BrilintaTicagrelor | 56 | $35,599 |
| Repatha SureclickEvolocumab | 37 | $28,379 |
| Metoprolol Succinate | 920 | $12,378 |
| VerquvoVericiguat | 15 | $10,113 |
| DapagliflozinDapagliflozin Propanediol | 14 | $6,932 |
| Ranolazine ErRanolazine | 110 | $6,546 |
| Atorvastatin Calcium | 518 | $4,221 |
| Amiodarone Hcl | 254 | $3,097 |
| Carvedilol | 483 | $3,074 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $364 | $862,587629 claims |
| NovartisEntresto | $487 | $399,220498 claims |
| AstraZenecaFarxiga, Brilinta | $111 | $277,738382 claims |
| Boehringer IngelheimJardiance | $220 | $107,858125 claims |
| Johnson & JohnsonXarelto | $62 | $90,445105 claims |
| MerckVerquvo | $228 | $10,11315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Thomasville
- Kashyap ChoksiThomasville$283K
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.